Published in Histopathology on April 03, 2014
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective. Front Oncol (2014) 0.91
ROS1 gene rearrangement and copy number gain in non-small cell lung cancer. Virchows Arch (2014) 0.89
Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. Int J Clin Exp Med (2015) 0.86
Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer (2015) 0.84
Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch (2016) 0.83
Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res (2015) 0.82
ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer (2014) 0.80
[Molecular diagnostics of non-small cell lung cancer: New markers and technologies]. Pathologe (2015) 0.80
Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. Thorac Cancer (2015) 0.79
ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. J Thorac Oncol (2017) 0.77
Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer (2016) 0.77
[Diagnosis, prognosis, and prediction of non-small cell lung cancer : Importance of morphology, immunohistochemistry and molecular pathology]. Pathologe (2015) 0.77
Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement. BMC Cancer (2016) 0.75
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology (2016) 0.75
ROS1 copy number alterations are frequent in non-small cell lung cancer. Oncotarget (2016) 0.75
Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis. Oncotarget (2016) 0.75
Genetic changes of non-small cell lung cancer under neoadjuvant therapy. Oncotarget (2016) 0.75
Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Front Oncol (2017) 0.75
Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. Virchows Arch (2015) 0.75
Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. Oncotarget (2017) 0.75
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet (2006) 4.43
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol (2012) 4.30
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2014) 3.40
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe (2011) 3.05
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 3.00
Most pancreatic cancer resections are R1 resections. Ann Surg Oncol (2008) 2.79
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res (2006) 2.68
Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell (2011) 2.47
Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg (2007) 2.42
Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov (2013) 2.32
Management of iatrogenic tracheobronchial injuries: a retrospective analysis of 29 cases. Ann Thorac Surg (2007) 2.16
Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol (2011) 2.10
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer (2008) 2.10
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res (2011) 2.08
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology (2006) 2.05
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer (2008) 2.02
Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice. Cell (2007) 1.96
Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol (2012) 1.90
Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol (2008) 1.89
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82
The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol (2010) 1.81
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med (2010) 1.80
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res (2004) 1.79
Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet (2012) 1.77
Efficacy and safety of TachoSil® versus standard treatment of air leakage after pulmonary lobectomy. Eur J Cardiothorac Surg (2010) 1.73
K25 (K25irs1), K26 (K25irs2), K27 (K25irs3), and K28 (K25irs4) represent the type I inner root sheath keratins of the human hair follicle. J Invest Dermatol (2006) 1.72
Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer (2008) 1.71
Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology (2008) 1.68
Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc Natl Acad Sci U S A (2008) 1.64
Incidence and treatment modalities of tracheobronchial injuries in Germany. Interact Cardiovasc Thorac Surg (2009) 1.64
Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63
Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology (2012) 1.63
Pseudo-pseudo Meigs' syndrome. Lancet (2005) 1.63
Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis (2004) 1.62
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol (2006) 1.59
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol (2012) 1.59
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.58
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int (2011) 1.57
Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology (2011) 1.57
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (2003) 1.55
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Arch (2010) 1.55
Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother (2013) 1.53
Methanobactin reverses acute liver failure in a rat model of Wilson disease. J Clin Invest (2016) 1.52
Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res (2004) 1.50
Intraoperative radiofrequency ablation of lung metastases and histologic evaluation. Ann Thorac Surg (2009) 1.49
Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology (2007) 1.48
Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer (2010) 1.47
High salt intake causes adverse fetal programming--vascular effects beyond blood pressure. Nephrol Dial Transplant (2012) 1.46
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest (2003) 1.45
Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol (2006) 1.45
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int (2011) 1.44
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol (2011) 1.44
Influence of different implantation techniques on AV valve competence after orthotopic heart transplantation. Eur J Cardiothorac Surg (2005) 1.43
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42
Occult cytomegalovirus cholangitis as a potential cause of cholestatic complications after orthotopic liver transplantation? A study of cytomegalovirus DNA in bile. Liver Transpl (2013) 1.42
Noncompaction myocardium in association with type Ib glycogen storage disease. Pathol Res Pract (2012) 1.41
Resistance of keratinocytes to TGFbeta-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. J Cell Sci (2002) 1.41
Regulation of DMBT1 via NOD2 and TLR4 in intestinal epithelial cells modulates bacterial recognition and invasion. J Immunol (2007) 1.40
Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 1.40
Serum versus intrahepatic HCV RNA and liver histology. Hepatology (2002) 1.39
Screening for Helicobacter pylori in Idiopathic Pulmonary Fibrosis Lung Biopsies. Respiration (2015) 1.39
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn (2009) 1.38
Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn (2013) 1.37
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood (2012) 1.36
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology (2002) 1.35
Detection and segmentation of cell nuclei in virtual microscopy images: a minimum-model approach. Sci Rep (2012) 1.35
Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol (2010) 1.35